Comparison of low-density lipoprotein cholesterol lowering by pravastatin to < 100 mg/dl versus > 100 mg/dl on brachial artery vasoreactivity in patients with severe hypercholesterolemia and previous atherosclerotic events or diabetes mellitus

被引：9

作者：

Lekakis, JP ^{[1
]}

Papamichael, CM ^{[1
]}

Barbaki, P ^{[1
]}

Papaioannou, TG ^{[1
]}

Stamatelopoulos, KS ^{[1
]}

Dagre, AG ^{[1
]}

Stamatelopoulos, SF ^{[1
]}

机构：

[1] Alexandra Univ Hosp, Dept Clin Therapeut, Athens, Greece

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 89卷 / 07期

关键词：

D O I：

10.1016/S0002-9149(02)02200-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In 30 patients with hypercholesterolemia and previous atherosclerotic events or diabetes mellitus, endothelium-dependent, flow-mediated dilatation of the brachial artery was determined before and after 6-month treatment with pravastatin. A final low-density lipoprotein cholesterol <100 mg/dl did not offer any additional benefit regarding improvement in endothelial function versus a more modest strategy with final low-density lipoprotein cholesterol similar to130 mg/dl.

引用

页码：857 / +

页数：5

共 10 条

[1] THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].

ANDERSON, TJ ;

MEREDITH, IT ;

YEUNG, AC ;

FREI, B ;

SELWYN, AP ;

GANZ, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493

[2] NONINVASIVE DETECTION OF ENDOTHELIAL DYSFUNCTION IN CHILDREN AND ADULTS AT RISK OF ATHEROSCLEROSIS [J].

CELERMAJER, DS ;

SORENSEN, KE ;

GOOCH, VM ;

SPIEGELHALTER, DJ ;

MILLER, OI ;

SULLIVAN, ID ;

LLOYD, JK ;

DEANFIELD, JE .

LANCET, 1992, 340 (8828) :1111-1115

[3] Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events? [J].

Cohen, JD ;

Drury, JH ;

Ostdiek, J ;

Finn, J ;

Babu, BRV ;

Flaker, G ;

Belew, K ;

Donohue, T ;

Labovitz, A .

AMERICAN HEART JOURNAL, 2000, 139 (04) :734-738

[4] REDUCTION IN SERUM-CHOLESTEROL WITH PRAVASTATIN IMPROVES ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA [J].

EGASHIRA, K ;

HIROOKA, Y ;

KAI, H ;

SUGIMACHI, M ;

SUZUKI, S ;

INOU, T ;

TAKESHITA, A .

CIRCULATION, 1994, 89 (06) :2519-2524

[5] HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease [J].

Järvisalo, MJ ;

Toikka, JO ;

Vasankari, T ;

Mikkola, J ;

Viikari, JSA ;

Hartiala, JJ ;

Raitakari, OT .

ATHEROSCLEROSIS, 1999, 147 (02) :237-242

[6] Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month [J].

ODriscoll, G ;

Green, D ;

Taylor, RR .

CIRCULATION, 1997, 95 (05) :1126-1131

[7] Improvement in endothelium-dependent brachial artery flow-mediated vasodilation with low-density lipoprotein cholesterol levels <100 mg/dl [J].

Shechter, M ;

Sharir, M ;

Labrador, MJP ;

Forrester, J ;

Merz, CNB .

AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (11) :1256-+

[8] BENEFICIAL-EFFECTS OF CHOLESTEROL-LOWERING THERAPY ON THE CORONARY ENDOTHELIUM IN PATIENTS WITH CORONARY-ARTERY DISEASE [J].

TREASURE, CB ;

KLEIN, JL ;

WEINTRAUB, WS ;

TALLEY, JD ;

STILLABOWER, ME ;

KOSINSKI, AS ;

ZHANG, J ;

BOCCUZZI, SJ ;

CEDARHOLM, JC ;

ALEXANDER, RW .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :481-487

[9]

Vita JA, 2000, CIRCULATION, V102, P846

[10] Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men [J].

Vogel, RA ;

Corretti, MC ;

Plotnick, GD .

AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (01) :37-40

← 1 →

Comparison of low-density lipoprotein cholesterol lowering by pravastatin to &lt; 100 mg/dl versus &gt; 100 mg/dl on brachial artery vasoreactivity in patients with severe hypercholesterolemia and previous atherosclerotic events or diabetes mellitus

Comparison of low-density lipoprotein cholesterol lowering by pravastatin to < 100 mg/dl versus > 100 mg/dl on brachial artery vasoreactivity in patients with severe hypercholesterolemia and previous atherosclerotic events or diabetes mellitus